CYCC Research and Charts

CYCC - Cyclacel Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2017-08-14 (Delayed quote data 2025-06-30)

Last 0.33	Change ⇓ 0.00 (0.00%)	Volume 399,305
	Open 0.33	High 0.33	Low 0.32

8EMA (Daily) 0.36	40EMA (Daily) 1.45	50EMA (Daily) 1.80	STO (Daily) 23.314	MACD Hist (Daily) 0.174
8EMA (Weekly) 1.069	40EMA (Weekly) 8.86	50EMA (Weekly) 14.32	STO (Weekly) 1.330	MACD Hist (Weekly) 0.717


Company Profile
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.